白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600332 白云山

已收盘 12-19 15:00:00

{"stockData":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"白云山","latestPrice":28.89,"timestamp":1734591600000,"preClose":28.8,"halted":0,"volume":4585796,"delay":0,"floatShares":1406000000,"shares":1626000000,"eps":2.1057,"marketStatus":"已收盘","marketStatusCode":5,"change":0.09,"latestTime":"12-19 15:00:00","open":28.65,"high":28.89,"low":28.52,"amount":132000000,"amplitude":0.0128,"askPrice":28.89,"askSize":278,"bidPrice":28.85,"bidSize":362,"shortable":0,"etf":0,"ttmEps":2.1057,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"adjPreClose":28.8,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":31.68,"lowLimit":25.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1625790949,"pbRate":1.3,"roa":"--","roe":"8.81%","epsLYR":2.495,"committee":-0.077283,"marketValue":46969000000,"floatMarketCap":40616000000,"peRate":13.719903,"changeRate":0.0031,"turnoverRate":0.0033,"status":0},"requestUrl":"/m/hq/s/600332","defaultTab":"news","newsList":[{"id":"2491955349","title":"白云山子公司注射用头孢唑肟钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2491955349","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491955349?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:11","pubTimestamp":1734081060,"startTime":"0","endTime":"0","summary":"控股子公司天心制药收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，其注射用头孢唑肟钠已通过仿制药质量和疗效一致性评价。这一药品于2014年上市，天心制药于2023年11月27日向国家药监局递交一致性评价申请，并于2023年12月6日获得受理。根据公告，天心制药在该药品一致性评价研发项目上已投入研发费用约为272万元（未审计），2023年该药品的销售收入为615万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213171404ab74e14d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213171404ab74e14d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1197","BK1606","BK1521","00874","600332","BK1515","BK1191"],"gpt_icon":0},{"id":"2491534951","title":"白云山(00874)：注射用头孢唑肟钠(1.0g、0.5g)已通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2491534951","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491534951?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:04","pubTimestamp":1734080665,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，广州白云山医药集团股份有限公司(以下简称“本公司”)控股子公司广州白云山天心制药股份有限公司(以下简称“天心制药”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，注射用头孢唑肟钠(1.0g、0.5g)已通过仿制药质量和疗效一致性评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600332","BK0183","BK1515","BK0028","BK0096","BK1191","BK0188","BK0175","BK0070","BK0012","BK0097","BK0196","BK0239","BK1197","BK1606","00874","BK1521"],"gpt_icon":0},{"id":"2491349352","title":"白云山最新公告：子公司天心制药注射用头孢唑肟钠（1.0g、0.5g）通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2491349352","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491349352?lang=zh_cn&edition=full","pubTime":"2024-12-13 17:01","pubTimestamp":1734080486,"startTime":"0","endTime":"0","summary":"白云山公告，公司控股子公司天心制药收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，注射用头孢唑肟钠（1.0g、0.5g）已通过仿制药质量和疗效一致性评价。该药品主要用于治疗敏感菌所致的下呼吸道感染、尿路感染等疾病。2023年注射用头孢唑肟钠在中国公立医院的销售额为37.9956亿元。天心制药在该项目上已投入研发费用约为272.02万元。通过一致性评价将有利于提升该产品的市场竞争力。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121300029386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","BK0188","BK0196","BK1521","BK0183","600332","BK0028","BK1191","BK1197","BK0070","BK0096","01477","BK1515","BK1606","BK0012","BK1574","00874","BK0097"],"gpt_icon":0},{"id":"2491346818","title":"白云山(600332.SH)子公司天心制药药品通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2491346818","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491346818?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:51","pubTimestamp":1734079891,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(600332.SH)公告，近日，公司控股子公司广州白云山天心制药股份有限公司(简称“天心制药”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，注射用头孢唑肟钠(1.0g、0.5g)已通过仿制药质量和疗效一致性评价。据悉，头孢唑肟钠属于第三代头孢菌素，主要用于治疗敏感菌所致的下呼吸道感染、尿路感染、腹腔感染、盆腔感染、败血症、皮肤软组织感染、骨和关节感染、肺炎链球菌或流感嗜血杆菌所致脑膜炎和单纯性淋病等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1224569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK1521","BK0012","BK0097","600332","BK1515","BK0070","01477","BK0028","00874","BK0196","BK1191","BK0188","BK1197","BK0239","BK0096","BK0183","BK1606","BK1574"],"gpt_icon":0},{"id":"2491134579","title":"白云山：注射用头孢唑肟钠通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2491134579","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491134579?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:48","pubTimestamp":1734079697,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0012","BK0196","BK1606","BK0175","BK0188","BK0097","00874","BK1191","BK0239","BK1197","BK0028","01477","BK0183","BK1574","600332","BK0096","BK1521","BK1515","BK0070"],"gpt_icon":0},{"id":"2489288310","title":"白云山：公司将按程序及时补选董事及选举产生董事长，继续经营好公司业绩，给投资者更大的回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2489288310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489288310?lang=zh_cn&edition=full","pubTime":"2024-12-06 19:00","pubTimestamp":1733482817,"startTime":"0","endTime":"0","summary":"证券之星消息，白云山(600332)12月06日在投资者关系平台上答复投资者关心的问题。投资者：请问公司董事长准备选多久？公司市值十几年如一日，谁来无所谓，都一样！失望至极！白云山董秘：感谢您的关注。公司将按程序及时补选董事及选举产生董事长，继续经营好公司业绩，给投资者更大的回报。投资者：你好，请问公司代理董事长杨军先生是否已经成为公司正式董事长?白云山董秘：感谢您的关注。公司目前由副董事长杨军先生代行董事长职责。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600036467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["00874","BK1521","BK0070","BK0175","600332","BK0012","BK0183","BK0097","BK1515","BK0188","BK1606","BK1191","BK0196","BK0028","BK1197","BK0239","BK0096"],"gpt_icon":0},{"id":"2489446287","title":"【机构调研记录】招商基金调研海南华铁、白云山等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2489446287","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489446287?lang=zh_cn&edition=full","pubTime":"2024-12-06 08:02","pubTimestamp":1733443376,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月5日披露的机构调研信息，招商基金近期对5家上市公司进行了调研，相关名单如下：1）海南华铁 个股亮点：2024年7月26日，公司控制权发生变更，公司控股股东变更为海南海控产业投资有限公司，实际控制人变更为海南省国有资产监督管理委员会；控股子公司上海科思翰智算与上海无问芯穹无达成深度战略合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600006960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["00874","603300","BK0096","BK0070","BK0183","BK0188","BK1515","BK0203","BK0028","BK0175","600332","BK1191","BK0196","BK1197","BK0239","BK0097","BK1606","BK0012","BK1521"],"gpt_icon":0},{"id":"2488900919","title":"白云山：11月29日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2488900919","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488900919?lang=zh_cn&edition=full","pubTime":"2024-12-03 19:03","pubTimestamp":1733223838,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月3日白云山发布公告称公司于2024年11月29日召开业绩说明会。白云山2024年三季报显示，公司主营收入590.6亿元，同比上升1.5%；归母净利润31.59亿元，同比下降16.68%；扣非净利润28.56亿元，同比下降16.95%；其中2024年第三季度，公司单季度主营收入180.17亿元，同比下降1.08%；单季度归母净利润6.09亿元，同比下降37.82%；单季度扣非净利润5.15亿元，同比下降38.7%；负债率51.99%，投资收益1.91亿元，财务费用204.27万元，毛利率17.7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120300033200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0096","BK0175","BK1197","BK0183","BK1606","BK1515","BK0188","00874","BK0070","BK0196","BK0097","BK1191","BK0239","600332","BK1521"],"gpt_icon":0},{"id":"2488616042","title":"南向资金11月29日净买入白云山21.00万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2488616042","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488616042?lang=zh_cn&edition=full","pubTime":"2024-12-02 09:30","pubTimestamp":1733103009,"startTime":"0","endTime":"0","summary":"11月29日, 南向资金增持白云山21.00万股，连续5日增持。截止当日收盘，港股通共持有白云山12581.26万股，占流通股57.20%。白云山近5个交易日上涨2.26%，港股通累计增持266.00万股；近20个交易日下跌1.31%，港股通累计增持1018.20万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202093039a264d967&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202093039a264d967&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","BK0239","BK0028","BK0188","600332","BK0070","BK0097","BK0175","BK0096","BK0012","BK0183"],"gpt_icon":0},{"id":"2487753905","title":"白云山预计2025年度日常关联交易总额超8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487753905","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487753905?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:59","pubTimestamp":1732874340,"startTime":"0","endTime":"0","summary":"财中社11月29日电白云山（600332/00874）发布关于2025年度日常关联交易预计的公告。公司及其附属企业2025年度预计与广州白云山和记黄埔中药有限公司（“白云山和黄”）、广州百特侨光医疗用品有限公司（“百特侨光”）及广州白云山一心堂医药投资发展有限公司（“白云山一心堂”）及其附属企业之间发生的日常关联交易金额分别不超过4.38亿元、2.21亿元及1.88亿元。此次日常关联交易无需提交股东大会审议，且不对关联方形成较大依赖，有利于公司业务的持续发展。2024年前三季度，白云山实现收入590.60亿元，归母净利润31.59亿元。（文章来源：财中社）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129181347a25ee8a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129181347a25ee8a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0196","BK0097","00874","BK0183","BK0012","BK0096","BK0028","BK0239","BK0070","600332","BK0188"],"gpt_icon":0},{"id":"2487613533","title":"白云山回应旗下公司资金不统一管理问题：各板块对资金存在不同的周期需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2487613533","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487613533?lang=zh_cn&edition=full","pubTime":"2024-11-29 17:05","pubTimestamp":1732871123,"startTime":"0","endTime":"0","summary":"11月29日，白云山举办2024年第三季度业绩说明会。还有投资者质疑，广药白云山为何不统一对旗下公司资金进行统一管理。由于四大板块各有特色，并且产业具有周期性特点，各大板块对资金存在不同的周期需求，公司将继续做好资金管理工作，通过多种渠道方式降低资金使用成本，提高资金使用效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129170603abe83250&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129170603abe83250&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0028","BK0096","BK0175","BK0183","BK0188","00874","BK0070","BK0196","BK0097","BK0239","600332"],"gpt_icon":0},{"id":"2487581782","title":"白云山向兴证资管出售应收账款5.24亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2487581782","media":"新京报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487581782?lang=zh_cn&edition=full","pubTime":"2024-11-29 15:40","pubTimestamp":1732866000,"startTime":"0","endTime":"0","summary":"新京报讯 11月29日，白云山发布公告，非全资附属公司广州医药与兴证资管根据基础资产买卖协议签订新增基础资产交割确认函，确认向兴证资管出售第一次新增基础资产，并收到购买价款5.24亿元。白云山拥有广州医药90.92%股权，广州医药及其附属公司主要从事各类医药产品的分销及零售，并致力于向医药行业价值链上下游的合作伙伴提供供应链服务。在白云山看来，广州医药通过该等交易项下的交易利用应收账款进行资产证券化，可以将应收账款转变为流动性较高的现金资产，达到盘活资产存量的目的。校对 赵琳","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129154618a25e8f57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129154618a25e8f57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","BK0183","BK0188","BK0012","BK0196","BK0239","BK0028","BK0175","BK0070","BK0097","600332"],"gpt_icon":0},{"id":"2487589923","title":"白云山11月29日遭主力抛售121万元 环比增加188.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487589923","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487589923?lang=zh_cn&edition=full","pubTime":"2024-11-29 15:18","pubTimestamp":1732864696,"startTime":"0","endTime":"0","summary":"11月29日, 白云山股价涨1.04%，报收29.01元，成交金额2.45亿元，换手率0.60%，振幅2.02%，量比1.20。白云山今日主力资金净流出121万元，上一交易日主力净流出42万元，今日环比增加188.10%。该股近5个交易日上涨3.39%，主力资金累计净流入1585万元；近20日主力资金累计净流出9189万元，其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129152224a25e7f17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129152224a25e7f17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600332","BK0175","BK0183","BK0188","BK0070","BK0012","BK0239","BK0028","BK0096","BK0196","BK0097"],"gpt_icon":0},{"id":"2487588721","title":"广药集团“迎新” 白云山“一把手”悬而未定","url":"https://stock-news.laohu8.com/highlight/detail?id=2487588721","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487588721?lang=zh_cn&edition=full","pubTime":"2024-11-29 09:46","pubTimestamp":1732844816,"startTime":"0","endTime":"0","summary":"广药集团迎来了新任董事长。随着广药集团新董事长的到任，谁将接任白云山的“一把手”，也成为外界关注的焦点。广药集团新董事长李小军履职后，能否为上市公司白云山及参股公司康美药业注入新的活力，令投资者关注。新京报记者张兆慧文章来源：新京报文章作者：张兆慧广药集团“迎新” 白云山“一把手”悬而未定","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129095909a25dd460&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129095909a25dd460&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00874","BK1521","600332","BK1515","BK1606","BK1191","BK1197"],"gpt_icon":0},{"id":"2487375391","title":"海外不确定性落地，A股核心资产受追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=2487375391","media":"银华基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487375391?lang=zh_cn&edition=full","pubTime":"2024-11-29 08:17","pubTimestamp":1732839421,"startTime":"0","endTime":"0","summary":"导语：回顾2024年，巨大的“不确定性”成为全球市场的核心特征。另一方面，不确定性来自于全球大选背景下的政治周期讨论，“新政策与新格局走向何方”备受瞩目。展望未来，A股核心资产有望迎来资产负债表修复和投资者预期重构，配置窗口期显现。其中，A500指数作为A股新时代的核心宽基指数，正逐渐成为投资者的新焦点。A500指数发布不足2个月超82只基于A500指数的基金产品申报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129081447971a91b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241129081447971a91b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600919","BK0280","600760","600233","600183","600741","600886","600019","600219","600600","BK0183","600309","600188","600036","600515","600031","600115","600015","600346","600900","601088","601100","600196","BK0012","600674","600918","601225","601236","600745","600029","600085","600018","600989","600519","601186","BK0028","600489","600999","601169","600028","601066","600584","600958","600132","600893","601117","600875","600016","600406","600938","600362","600372","600276","600150","600161","600436","600011","600460","600845","600926","600803","600732","600089","600104","600941","600026","600426","601012","600332","600660","601111","600025","601229","600023","600050","601021","601009","600176","600905","600048","601238","600061","600438","600585","600690","600010","600111","601138","BK0010","600588","600415","159982","600027","BK0006","601059","BK0188","BK0187","600009","BK0196","600030","601211","600570","600809","BK0164","399300","601006","600039","600887","BK0000","600547","600837","600795"],"gpt_icon":0},{"id":"2486119398","title":"白云山(00874.HK)附属以逾5.2亿人民币向兴证资管应收账款","url":"https://stock-news.laohu8.com/highlight/detail?id=2486119398","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486119398?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:16","pubTimestamp":1732785360,"startTime":"0","endTime":"0","summary":"白云山(00874.HK) 公布，持股90.92%的非全资附属公司广州医药，于11月28日与兴证资管签订新增基础资产交割确认函，向兴证资管出售第一次新增基础资产，即是账面值为约5.31亿元人民币的应收账款，代价为5.24亿元人民币。公司表示，广州医药通过交易可利用应收账款进行资产证券化，从而将应收账款转变为流动性较高的现金资产，达到盘活资产存量的目的。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-28 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200309160210932_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200309160210932_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400312/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0183","BK0175","600332","BK0188","BK0239","BK0012","BK1197","BK0196","BK1515","BK0096","BK0097","BK1191","BK1521","BK0070","BK1606","BK0028","00874"],"gpt_icon":0},{"id":"2486360031","title":"白云山(00874)：广州医药向兴证资管出售应收账款","url":"https://stock-news.laohu8.com/highlight/detail?id=2486360031","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486360031?lang=zh_cn&edition=full","pubTime":"2024-11-28 17:13","pubTimestamp":1732785233,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，于2024年11月28日，广州医药与兴证资管根据基础资产买卖协议(第四期)签订《新增基础资产交割确认函》，确认向兴证资管出售第一次新增基础资产，并收到购买价款人民币5.24亿元。第一次新增基础资产其为账面值人民币5.31亿元的应收账款。广州医药通过该等交易项下的交易利用应收账款进行资产证券化，可以将应收账款转变为流动性较高的现金资产，达到盘活资产存量的目的。鉴于上述原因及本公告所披露的该等交易的条款，董事会认为该等交易的条款属公平合理，符合集团及公司股东的整体权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217267.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0012","BK0028","BK0239","BK0070","BK0097","BK1191","00874","BK1606","BK0096","BK0188","BK1521","159938","BK0175","09939","BK1515","BK1197","BK1161","BK0183","BK1574","600332"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600721","603108","BK0185","688163","603087","600976","600351","603858","600436","603939","688575","600380","600998","688331","603309","688266","600200","688278","600055","605199","603392","600161","600521","BK0070","600572","688192","688276","603439","600771","688506","688315","603567","600511","BK0096","688298","688356","600329","688193","600332","688581","688180","688336","600851","688076","688139","688198","600196","603127","600085","600129","688656","600080","603301","603658","600566","688373","688189","688067","605177","BK0012","600867","688221","688050","688488","688578","688687","688212","688105","688301","688670","600056","688046","688382","688091","688389","603456","688062","688085","603707","688566","600739","688235","688247","688428","600079","600062","688520","600763","603882","BK0239","688177","159938","603259","600252","603538","603896","688029","600420","688117","688658","688073","688351","BK0188","688222","688137","601607","688202","603590","600422","600535","688626","BK0028","688114","688176","600529","688690","600276","688443","600211","600285","688617","688767","688271","688321","688166","603367","603233","688161","600488"],"gpt_icon":0},{"id":"2486847900","title":"白云山：江南卷柏片获得药品补充申请批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2486847900","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486847900?lang=zh_cn&edition=full","pubTime":"2024-11-27 19:27","pubTimestamp":1732706826,"startTime":"0","endTime":"0","summary":"格隆汇11月27日丨白云山公布，公司分公司广州白云山医药集团股份有限公司白云山制药总厂收到国家药品监督管理局签发的《药品补充申请批准通知书》，药品通用名称：江南卷柏片。江南卷柏片具有清热凉血疗效，用于血热妄行所致的皮下紫斑，症见皮肤出现散在青紫斑点或斑块，舌红，苔黄，脉数等；原发性血小板减少性紫癜见上述血热证候者。该药品是白云山制药总厂独家品种。请读者仅作参考，并请自行承担全部责任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127193145abe3148d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127193145abe3148d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0028","BK0196","BK0070","BK0175","BK0239","BK0183","600332","BK0096","BK0097","BK0188"],"gpt_icon":0},{"id":"2486847559","title":"白云山(00874)：获得江南卷柏片《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2486847559","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486847559?lang=zh_cn&edition=full","pubTime":"2024-11-27 19:21","pubTimestamp":1732706470,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)发布公告，近日，公司分公司广州白云山医药集团股份有限公司白云山制药总厂(简称“白云山制药总厂”)收到国家药品监督管理局签发的《药品补充申请批准通知书》。江南卷柏片具有清热凉血疗效，用于血热妄行所致的皮下紫斑，症见皮肤出现散在青紫斑点或斑块，舌红，苔黄，脉数等;原发性血小板减少性紫癜见上述血热证候者。该药品是白云山制药总厂独家品种。截至本公告日，白云山制药总厂在江南卷柏片研发项目上已投入研发费用合计约人民币10万元(未审计)。2023年江南卷柏片的销售收入为人民币13.09万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1216818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK0183","BK0188","BK0096","BK0196","BK1515","600332","00874","BK1197","BK0239","BK0175","BK1191","BK0070","BK1606","BK0097","BK0028","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2001-02-06","address":"广东省广州市荔湾区沙面北街45号","stockEarnings":[{"period":"1week","weight":-0.0076},{"period":"1month","weight":0.0073},{"period":"3month","weight":0.1645},{"period":"6month","weight":-0.0096},{"period":"1year","weight":0.0512},{"period":"ytd","weight":0.0468}],"companyName":"广州白云山医药集团股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"162579万元","compareEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.2362},{"period":"6month","weight":0.1281},{"period":"1year","weight":0.1534},{"period":"ytd","weight":0.1369}],"survey":"　　广州白云山医药集团股份有限公司主营业务中西成药、化学原料药、天然药物、生物医药、化学原料药中间体的研究开发、制造与销售;西药、中药和医疗器械的批发、零售和进出口业务;大健康产品的研发、生产与销售;医疗服务、健康管理、养生养老等健康产业投资。公司产品主要包括中成药、中药饮片、化学制剂、化学原料药、医药流通。集团是全国最大的制药企业集团之一。本集团及合营企业拥有国家级研发机构7家，国家级企业技术中心1家，博士后工作站2家。","serverTime":1734604736103,"listedPrice":9.8,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供白云山(600332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"白云山,600332,白云山股票,白云山股票老虎,白云山股票老虎国际,白云山行情,白云山股票行情,白云山股价,白云山股市,白云山股票价格,白云山股票交易,白云山股票购买,白云山股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"白云山(600332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供白云山(600332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}